- Conditions
- Genital Herpes Simplex Type 2
- Interventions
- Matrix-M2, GEN-003, Placebo
- Biological · Drug
- Lead sponsor
- Genocea Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Diego, California • San Francisco, California + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 673–696
of 835
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Inflammatory Response
- Interventions
- Pneumovax 23, Typhim VI, Saline
- Drug · Other
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 249 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- College Station, Texas
- Conditions
- Cytomegalovirus Infection
- Interventions
- mRNA-1647, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Seattle, Washington
- Conditions
- Gastroenteritis
- Interventions
- NoV GI.1/GII.4 Bivalent VLP Vaccine, Saline
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 3
- States / cities
- Silver Springs, Maryland • St Louis, Missouri • Rochester, New York
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- Hiltonol, Citarinostat, Lenalidomide, PVX-410
- Drug · Biological
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
- Conditions
- Influenza
- Interventions
- Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Norfolk, Virginia
- Conditions
- Influenza, Pandemic
- Interventions
- BW-1014: 25 µg rH5 in 20% NE - pipette - IN, BW-1014: 50 µg rH5 in 20% NE - pipette - IN, BW-1014: 100 µg rH5 in 20% NE - pipette - IN, rH5 (100 µg) control - pipette - IN, Saline (Placebo) - pipette - IN, H5N1 IIV - IM
- Biological
- Lead sponsor
- BlueWillow Biologics
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Virus Diseases
- Interventions
- Low dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Medium dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lower dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Lowest dose formulation of RG SAM (CNE) vaccine (GSK3903133A), Saline Placebo, RabAvert
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2022
- U.S. locations
- 4
- States / cities
- South Miami, Florida • Lenexa, Kansas • Baltimore, Maryland + 1 more
- Conditions
- Herpes Genitalis
- Interventions
- VCL-HB01, Phosphate-buffered saline
- Biological · Other
- Lead sponsor
- Vical
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 261 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • San Diego, California • Hollywood, Florida + 12 more
- Conditions
- Plague Vaccine
- Interventions
- rF1V vaccine (with Adjuvant), rF1V vaccine (without Adjuvant)
- Biological
- Lead sponsor
- DynPort Vaccine Company LLC, A GDIT Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 402 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 11
- States / cities
- San Francisco, California • Santa Ana, California • Lenexa, Kansas + 8 more
- Conditions
- Asthma
- Interventions
- Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 21 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Huntington Beach, California + 19 more
- Conditions
- Pneumococcal Infections, Pneumococcal Vaccines
- Interventions
- V114, Prevnar 13™, RotaTeq™, Pentacel™, RECOMBIVAX HB™, VAQTA™, MMR II™, VARIVAX™, HIBERIX™
- Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 42 Days to 90 Days
- Enrollment
- 1,720 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Opp, Alabama + 58 more
- Conditions
- Ricin Poisoning
- Interventions
- RVEc
- Biological
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 18 Years to 50 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Fort Deterick, Maryland
- Conditions
- Vaccine Reaction
- Interventions
- MicronJet, Fluzone® Quadrivalent, Fluzone® High Dose Quadrivalent
- Device · Biological
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 139 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Seasonal Influenza
- Interventions
- mRNA-1011.1, mRNA-1011.2, mRNA-1012.1, mRNA-1010, mRNA-1010.2, mRNA-1010.3
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 698 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 22
- States / cities
- Lakewood, California • Long Beach, California • Fort Collins, Colorado + 19 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Upadacitinib, Pneumococcal 13-valent conjugate vaccine (PCV-13)
- Drug · Biological
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 493 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 52
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Hemet, California + 44 more
- Conditions
- COVID-19
- Interventions
- ChAdV68-S, ChAdV68-S-TCE, SAM-LNP-S, SAM-LNP-S-TCE, Sodium Chloride, 0.9%
- Biological · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 4
- States / cities
- Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more
- Conditions
- Healthy
- Interventions
- Ixekizumab, Boostrix®, Pneumovax®23
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 3
- States / cities
- Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas
- Conditions
- Influenza, Swine-origin A/H1N1 Influenza
- Interventions
- Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant, Monovalent Subvirion A/H1N1 influenza vaccine, Normal saline solution
- Biological
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 548 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2011
- U.S. locations
- 15
- States / cities
- Anaheim, California • Fountain Valley, California • South Miami, Florida + 11 more
- Conditions
- Tetanus, Diphtheria, Pertussis, Whooping Cough
- Interventions
- Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 11 Years to 12 Years
- Enrollment
- 423 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 8
- States / cities
- Sacramento, California • Bardstown, Kentucky • Woburn, Massachusetts + 5 more
- Conditions
- Virus, Zika, Zika Virus Disease, Flavivirus Infections, Healthy Participants
- Interventions
- Placebo, PIZV
- Drug · Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 271 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 7
- States / cities
- Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more
- Conditions
- Norovirus Acute Gastroenteritis
- Interventions
- mRNA-1403, mRNA-1405, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,407 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 14
- States / cities
- Long Beach, California • Longmont, Colorado • Hollywood, Florida + 11 more
- Conditions
- HIV Infection
- Interventions
- 300 ug FLSC vaccine, 150 ug FLSC vaccine, 75 ug FLSC vaccine, Placebo
- Biological
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- SARS CoV 2 Infection
- Interventions
- IMNN-101
- Biological
- Lead sponsor
- Imunon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania